Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139561 | 0.92 | GPR119 (0.50) | GPR119CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL6531969 | 0.84 | GPR119 (0.56) | GPR119KCNH2CYP2C9 | |
| SCHEMBL388432 | 0.83 | GPR119 (0.69) | GPR119CYP3A4CYP2C19KCNH2CYP2C9 | |
| SCHEMBL5138883 | 0.83 | GPR119 (0.70) | GPR119KCNH2CYP2C9 | |
| SCHEMBL5139292 | 0.82 | GPR119 (0.49) | GPR119KCNH2CYP2C9 | |
| SCHEMBL5140388 | 0.82 | GPR119 (0.50) | GPR119KCNH2CYP2C9 | |
| SCHEMBL5140401 | 0.81 | GPR119 (0.49) | GPR119KCNH2CYP2C9 | |
| SCHEMBL5138895 | 0.81 | GPR119 (0.51) | GPR119KCNH2CYP2C9 | |
| SCHEMBL5146284 | 0.80 | GPR119 (0.54) | GPR119KCNH2CYP2C9 | |
| SCHEMBL390965 | 0.80 | GPR119 (0.68) | GPR119CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470699-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, SULT2A1 | GPR119 13/4885CYP3A4 33/4885CYP2C19 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.